Private Prescription: Wegovy vs Mounjaro Expert Analysis
Why Private Prescription Makes Wegovy or Mounjaro Which is Better Decision Easier
Determining Wegovy or Mounjaro which is better through private prescription eliminates the complex NHS pathway that requires GP referral to specialist weight management services. Private assessment allows comprehensive evaluation of both treatments simultaneously, with prescribers reviewing your medical history, current medications, and weight management goals to recommend the most appropriate option. The private route provides access to detailed comparison consultations that NHS time constraints often prevent, ensuring you receive personalised guidance on whether Wegovy's proven GLP-1 mechanism or Mounjaro's dual GIP/GLP-1 approach suits your individual circumstances better.
EverydayMeds registered pharmacy services (GPhC #9012878) offer transparent comparison between both prescription-only medicines without the lengthy specialist referral process. Our qualified prescribers have extensive experience with both treatments and can explain the practical differences in dosing schedules, storage requirements, and expected treatment progression. This individualised approach ensures the decision of Wegovy or Mounjaro which is better is based on clinical evidence rather than availability constraints that often influence NHS prescribing patterns.
Wegovy vs Mounjaro Pricing: Private Prescription Value Analysis
Understanding the cost implications helps determine Wegovy or Mounjaro which is better for your budget and treatment duration. Wegovy pricing starts at £79.99 for the 0.25mg starter dose (with FIRST40 discount applied at checkout), progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. Our Getting Started bundles provide convenient dose progression, such as the Intro Duo (0.25mg & 0.5mg) for £169.99, eliminating multiple ordering requirements during initial treatment phases. Returning customers benefit from the DOSE25 discount code applied automatically at checkout.
Mounjaro pricing follows a different structure reflecting its dual-hormone mechanism, though direct cost comparison requires individual assessment based on prescribed dosing schedules and treatment response. Bundle options for both medications include the Ultimate Stability Trio providing three months of maintenance supply, ensuring treatment continuity without monthly reordering. The pricing transparency allows informed decision-making about Wegovy or Mounjaro which is better for your long-term financial planning, with both treatments representing significant investment in medically-supervised weight management.
Clinical Evidence: Wegovy or Mounjaro Which is Better Research Comparison
Clinical trial data provides objective evidence when considering Wegovy or Mounjaro which is better, though direct head-to-head comparisons remain limited due to different study populations and endpoints. Wegovy's STEP 1 trial demonstrated approximately 15% average weight loss at 68 weeks in adults with obesity, while the SELECT cardiovascular outcomes trial showed 20% reduction in major cardiovascular events. These results reflect treatment alongside reduced-calorie diet and increased physical activity as per the licensed indication.
Mounjaro's SURMOUNT trials revealed the dual GIP/GLP-1 mechanism's potential, though comparing percentage weight loss directly between trials is inappropriate due to different methodologies and participant characteristics. The decision of Wegovy or Mounjaro which is better should be based on individual patient factors, medical history, and treatment goals rather than trial outcome comparisons. Both medications require prescription-only access with appropriate clinical oversight to monitor treatment response and manage potential side effects effectively.
How Wegovy Works: Understanding the GLP-1 Mechanism
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural incretin hormone produced in the intestine following food consumption. This mechanism reduces appetite by acting on brain appetite centres, promoting feelings of fullness after smaller meals, and potentially reducing food cravings throughout the day. The once-weekly injection provides sustained hormone levels that support consistent appetite regulation, making it easier to adhere to reduced-calorie dietary plans. Understanding this mechanism helps determine Wegovy or Mounjaro which is better based on your eating patterns and appetite control needs. The treatment works most effectively when combined with lifestyle modifications, as the medication enhances your ability to maintain dietary changes rather than replacing the need for healthy eating habits.
Private Prescription Ordering Process: Accessing Wegovy or Mounjaro
The streamlined private prescription process eliminates traditional barriers when deciding Wegovy or Mounjaro which is better for your circumstances. Complete our comprehensive 3-minute clinical assessment covering medical history, current medications, previous weight management attempts, and treatment preferences to provide prescribers with essential information for appropriate treatment selection. Qualified prescribers review applications within three working days (24-hour express review available), assessing suitability for either treatment based on licensed indications and contraindications. Once approved, both Wegovy and Mounjaro are dispatched via next-day delivery using cold-chain temperature-controlled packaging to maintain medication stability. Our GPhC registered pharmacy (#9012878) ensures all prescriptions meet UK regulatory standards for prescription-only medicine supply.
Storage and Practical Considerations: Wegovy vs Mounjaro Differences
Storage requirements differ between treatments and may influence Wegovy or Mounjaro which is better for your lifestyle needs. Wegovy offers superior travel convenience with six weeks room temperature storage below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both medications require refrigeration at 2-8°C before first use, delivered in temperature-controlled packaging to maintain pharmaceutical integrity. The FlexTouch pen design for Wegovy provides familiar injection experience for patients transitioning from other Novo Nordisk treatments, while Mounjaro utilises Eli Lilly's pen system. Dose escalation schedules differ between treatments, with Wegovy following a structured 16-week escalation to maintenance dose, requiring consideration of long-term treatment planning when determining which option better suits your circumstances.
Specialist Weight Management: Private vs NHS Treatment Pathways
Private prescription access transforms the decision process for Wegovy or Mounjaro which is better by eliminating NHS specialist service bottlenecks that can delay treatment initiation by six months or more. NHS pathways require GP referral to Tier 3 weight management services, often with strict BMI thresholds and comorbidity requirements that may exclude suitable candidates from either treatment option. Private assessment focuses on individual clinical need rather than service capacity constraints, allowing personalised evaluation of both treatments based on medical history and treatment goals.
The NICE TA875 recommendation for Wegovy includes specialist weight management support requirements that private services can provide more flexibly than overwhelmed NHS specialist teams. EverydayMeds prescribers offer ongoing clinical support throughout treatment, monitoring progress and side effects while providing the specialist oversight that optimises treatment outcomes. This enhanced support structure helps ensure the choice of Wegovy or Mounjaro which is better is continuously evaluated and adjusted based on individual treatment response.
Expert Treatment Selection: Clinical Decision Support
Professional guidance ensures the decision of Wegovy or Mounjaro which is better is based on comprehensive clinical assessment rather than limited information or availability constraints. Both medications require prescription-only access with qualified prescriber evaluation of contraindications, drug interactions, and suitability for individual patients based on medical history and current health status. Our experienced clinical team understands the nuanced differences between GLP-1-only and dual GIP/GLP-1 mechanisms, helping patients understand which approach may better suit their metabolic profile and treatment objectives. Treatment selection considers factors including previous medication responses, injection preferences, storage convenience, and long-term treatment planning to ensure optimal therapeutic outcomes. Start your consultation today at https://everydaymeds.co.uk/collections/wegovy using discount code FIRST40 for new customers or DOSE25 for returning patients, with expert prescriber support guiding your treatment decision throughout the assessment process.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
